Recro Pharma, a clinical-stage biotech developing non-opioid therapeutics for the treatment of pain, raised $30 million by offering 3.8 million shares at $8, below the range of $10 to $12. Recro Pharma plans to list on the NASDAQ under the symbol REPH. Aegis Capital Corp. acted as the lead manager on the deal.
